quinta-feira, 8 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 3, 2026

Apple debuts M5 Pro and M5 Max to supercharge the most demanding pro workflows

View original at finance.yahoo.com
Apple debuts M5 Pro and M5 Max to supercharge the most demanding pro workflows Built using the new Apple-designed Fusion Architecture, M5 Pro and M5 Max feature an advanced CPU, a next‑generation GPU with Neural Accelerators, and higher unified memory bandwidth for a massive increase in AI compute CUPERTINO, Calif., Ma…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Super core has the world's fastest single-threaded performance

    80% confidence
  • M5 Pro and M5 Max are the world's most advanced chips for pro laptops

    80% confidence
  • M5 Max CPU architecture offers up to 15 percent higher multithreaded performance when compared to M4 Max

    80% confidence
  • M5 Pro provides up to a 35 percent graphics uplift in apps using ray tracing compared to M4 Pro

    80% confidence
  • Both chips underscore relentless pace of innovation, integrating the world's fastest CPU cores, a next-generation GPU with Neural Accelerators, a faster Neural Engine, and high-bandwidth, high-capacity memory

    80% confidence
  • M5 Pro CPU architecture significantly boosts multithreaded performance by up to 30 percent for pro workloads compared to M4 Pro

    80% confidence
  • M5 Pro delivers up to 20 percent higher graphics performance than M4 Pro and 2.2x higher than M1 Pro

    80% confidence
  • CPU significantly boosts performance by up to 30 percent for pro workloads compared to previous generation

    80% confidence
  • M5 Pro delivers over 4x the peak GPU compute compared to M4 Pro, and over 6x the peak GPU compute than M1 Pro for AI performance

    80% confidence
  • M5 Pro and M5 Max are a monumental leap forward for Apple silicon, leveraging new Fusion Architecture to scale the capabilities of Apple silicon while preserving core tenets of performance, power efficiency, and unified memory architecture

    80% confidence
  • M5 Max provides a graphics uplift of up to 30 percent more than M4 Max for apps using ray tracing

    80% confidence
  • M5 Max offers over 4x the peak GPU compute compared to M4 Max, and over 6x the peak GPU compute than M1 Max for AI performance

    80% confidence
  • M5 Pro and M5 Max are over 4x the peak GPU compute for AI compared to the previous generation

    80% confidence
  • Super cores are the world's fastest CPU core

    80% confidence
  • Graphics performance for M5 Max is up to 20 percent higher than M4 Max and 2.2x higher than M1 Max

    80% confidence
  • Thunderbolt 5 implementation in M5 Pro and M5 Max is the industry's most capable implementation of Thunderbolt 5

    80% confidence
  • GPU increases graphics capabilities by up to 35 percent for apps using ray tracing than M4 Pro and M4 Max

    80% confidence
  • M5 Pro and M5 Max deliver up to 2.5x higher multithreaded performance than M1 Pro and M1 Max

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com